Search

Your search keyword '"Cortelazzo S"' showing total 418 results
Start Over Author "Cortelazzo S"
418 results on '"Cortelazzo S"'

2. P1245: CLINICAL IMPACT OF IMMUNOGLOBULIN HEAVY CHAIN REPERTOIRE IN MANTLE CELL LYMPHOMA: A STUDY FROM THE FONDAZIONE ITALIANA LINFOMI (FIL) PHASE III MCL0208 TRIAL.

Author

Alessandria, B., primary, Genuardi, E., additional, Civita, A. M., additional, Drandi, D., additional, Mantoan, B., additional, Ferrante, M., additional, Borriero, M., additional, Ragaini, S., additional, Bondielli, G., additional, Zaccaria, G. M., additional, Barbero, D., additional, Peri, V., additional, Hohaus, S., additional, Musuraca, G., additional, Cascavilla, N., additional, Ghiggi, C., additional, Tani, M., additional, Gaidano, G., additional, Volpetti, S., additional, Usai, S. V., additional, Di Renzo, N., additional, Cortelazzo, S., additional, Ladetto, M., additional, and Ferrero, S., additional

Published
2022
Full Text
View/download PDF

4. Early-stage diffuse large B cell lymphoma of the head and neck: clinico-biological characterization and 18 year follow-up of 488 patients (IELSG 23 study)

Author

Mian, M., Capello, D., Ventre, M. B., Grazio, D., Svaldi, M., Rossi, A., Tsang, R., Gospodarowicz, M. K., Oldani, E., Federico, M., Luminari, S., Marcheselli, L., Pogliani, E. M., Rossini, F., Cabrera, M. E., Martelli, M., Gutierrez-Garcia, G., Busetto, M., Visco, C., Fiegl, M., Rossi, D., Gaidano, G., Cavalli, F., Zucca, E., Rambaldi, A., Cortelazzo, S., and on behalf of the International Extranodal Lymphoma Study Group (IELSG)

Published
2014
Full Text
View/download PDF

5. A COMPLETELY GENETIC PROGNOSTIC MODEL OVERCOMES CLINICAL PROGNOSTICATORS IN MANTLE CELL LYMPHOMA: RESULTS FROM THE MCL0208 TRIAL FROM THE FONDAZIONE ITALIANA LINFOMI (FIL)

Author

Ferrero, S., primary, Moia, R., additional, Cascione, L., additional, Zaccaria, G. M., additional, Rinaldi, A., additional, Alessandria, B., additional, Grimaldi, D., additional, Favini, C., additional, Evangelista, A., additional, Schipani, M., additional, Narni, F., additional, Stelitano, C., additional, Stefani, P. M., additional, Benedetti, F., additional, Mian, M., additional, Casaroli, I., additional, Zanni, M., additional, Castellino, C., additional, Pavone, V., additional, Galimberti, S., additional, Re, F., additional, Rossi, D., additional, Cortelazzo, S., additional, Gaidano, G., additional, Ladetto, M., additional, and Bertoni, F., additional

Published
2021
Full Text
View/download PDF

10. Clofarabine and Treosulfan as Conditioning for Matched Related and Unrelated Hematopoietic Stem Cell Transplantation: Results from the Clo3o Phase II Trial

Author

Peccatori, J., Mastaglio, S., Giglio, F., Greco, R., Crocchiolo, R., Patriarca, F., Forno, B., Deola, S., Assanelli, A., Lupo Stanghellini, M. T., Marcatti, M., Zecca, M., Cortelazzo, S., Fanin, R., Fagioli, F., Locatelli, Franco, Ciceri, F., Locatelli F. (ORCID:0000-0002-7976-3654), Peccatori, J., Mastaglio, S., Giglio, F., Greco, R., Crocchiolo, R., Patriarca, F., Forno, B., Deola, S., Assanelli, A., Lupo Stanghellini, M. T., Marcatti, M., Zecca, M., Cortelazzo, S., Fanin, R., Fagioli, F., Locatelli, Franco, Ciceri, F., and Locatelli F. (ORCID:0000-0002-7976-3654)

Abstract

Allogeneic hematopoietic stem cell transplantation (allo-HSCT) can be curative for patients with hematologic malignancies. The ideal conditioning regimen before allo-HSCT has not been established. We conducted a Phase II study to evaluate the tolerability and efficacy of clofarabine and treosulfan as conditioning regimen before allo-HSCT. The primary objective was to evaluate the cumulative incidence of nonrelapse mortality (NRM) on day +100. Forty-four patients (36 with acute myelogenous leukemia, 5 with acute lymphoblastic leukemia, 3 with myelodysplastic syndromes) were enrolled. The median patient age was 47 years, and the median duration of follow-up was 27 months. The conditioning regimen was based on clofarabine 40 mg/m2 (days -6 to -2) and treosulfan 14 g/m2 (days -6 to -4). Allogeneic hematopoietic stem cells were derived from a sibling (n = 22) or a well-matched unrelated donor (n = 22). Graft-versus-host disease (GVHD) prophylaxis consisted of antithymocyte globulin, rituximab, cyclosporine, and a short-course of methotrexate. The regimen allowed for rapid engraftment and a 100-day NRM of 18%, due mainly to bacterial infections. The incidences of grade II-IV acute GVHD and chronic GVHD were 16% and 19%, respectively. The rates of overall survival (OS), progression-free survival, and relapse at 2 years were 51%, 31%, and 50%, respectively. Significantly different outcomes were observed between patients with low-intermediate and patients with high-very high Disease Risk Index (DRI) scores (1-year OS, 78% and 24%, respectively). Our findings show that the use of treosulfan and clofarabine as a conditioning regimen for allo-HSCT is feasible, with a 78% 1-year OS in patients with a low-intermediate DRI score. However, 1-year NRM was 18%, and despite the intensified conditioning regimen, relapse incidence remains a major issue in patients with poor prognostic risk factors.

Published
2020

11. The CIBMTR score predicts survival of AML patients undergoing allogeneic transplantation with active disease after a myeloablative or reduced intensity conditioning: a retrospective analysis of the Gruppo Italiano Trapianto Di Midollo Osseo

Author

Todisco, E, Ciceri, F, Oldani, E, Boschini, C, Micò, C, VanLint, M T, Donnini, I, Patriarca, F, Alessandrino, P E, Bonifazi, F, Arcese, W, Barberi, W, Marenco, P, Terruzzi, E, Cortelazzo, S, Santarone, S, Proia, A, Corradini, P, Tagliaferri, E, Falcioni, S, Irrera, G, Dallanegra, L, Castagna, L, Santoro, A, Camboni, A, Sacchi, N, Bosi, A, Bacigalupo, A, and Rambaldi, A

Published
2013
Full Text
View/download PDF

16. COMPREHENSIVE ANALYSIS OF BASELINE OUTCOME BIOPREDICTORS IN YOUNGER PATIENTS WITH MANTLE CELL LYMPHOMA: THE ANCILLARY BIOLOGICAL STUDIES OF FONDAZIONE ITALIANA LINFOMI (FIL) MCL0208 CLINICAL TRIAL

Author

Ferrero, S., Zaccaria, G. M., Barbero, D., Evangelista, A., Di Rocco, A., Re, A., Stefoni, V., Cavallo, F., Vitolo, U., Balzarotti, M., Rusconi, C., da Silva, Gomes M., Ghislieri, M., Omedè, P., Zamò, A., Ciccone, G., Gattei, V., Gaidano, G., Cortelazzo, S., and Ladetto, M.

Published
2019

17. PROGNOSTIC VALUE OF CLONAL HEMATOPOIESIS-MUTATIONS DETECTED AT DIAGNOSIS IN ACUTE MYELOID LEUKEMIA PATIENTS WITH NORMAL KARYOTYPE

Author

Caprioli, C, Spinelli, O, Salmoiraghi, S, Intermesoli, T, Zanghi, P, Cavagna, R, Michelato, A, Buklijas, K, Elidi, L, Delaini, F, Oldani, E, Gianfaldoni, G, Bosi, A, Marmont, F, Audisio, E, Ferrero, D, Terruzzi, E, De Paoli, L, Rossi, G, Borlenghi, E, Cavattoni, I, Tajana, M, Scattolin, Am, Mattei, D, Corradini, P, Campiotti, L, Ciceri, F, Bernardi, M, Todisco, E, Cortelezzi, A, Cortelazzo, S, Falini, B, Pavoni, C, Bassan, R, Rambaldi, A, and Lussana, F

Published
2019

19. Anthracycline-based chemotherapy as primary treatment for intravascular lymphoma

Author

Ferreri, A.J.M., Campo, E., Ambrosetti, A., Ilariucci, F., Seymour, J.F., Willemze, R., Arrigoni, G., Rossi, G., López-Guillermo, A., Berti, E., Eriksson, M., Federico, M., Cortelazzo, S., Govi, S., Frungillo, N., Dell'Oro, S., Lestani, M., Asioli, S., Pedrinis, E., Ungari, M., Motta, T., Rossi, R., Artusi, T., Iuzzolino, P., Zucca, E., Cavalli, F., and Ponzoni, M.

Published
2004
Full Text
View/download PDF

21. Patterns of Outcome and Prognostic Factors in Primary Large-Cell Lymphoma of the Testis in a Survey by the International Extranodal Lymphoma Study Group

Author

Zucca, E., Conconi, A., Mughal, T.I., Sarris, A.H., Seymour, J.F., Vitolo, U., Klasa, R., Ozsahin, M., Mead, G.M., Gianni, M.A., Cortelazzo, S., Ferreri, A.J.M., Ambrosetti, A., Martelli, M., Thiéblemont, C., Moreno, H. Gomez, Pinotti, G., Martinelli, G., Mozzana, R., Grisanti, S., Provencio, M., Balzarotti, M., Laveder, F., Oltean, G., Callea, V., Roy, P., Cavalli, F., and Gospodarowicz, M.K.

Published
2003

23. MOLECULAR PROLIFE BY NEXT GENERATION SEQUENCING OF ACUTE MYELOID LEUKEMIA WITH NORMAL KARYOTYPE: CLINICAL RESULTS FROM THE PROSPECTIVE TRIAL 02/06 OF THE NORTHERN ITALY LEUKEMIA GROUP (NILG)

Author

Spinelli, O, Salmoiraghi, S, Zanghi, P, Cavagna, R, Michelato, A, Buklijas, K, Zannino, L, Intermesoli, T, Lussana, F, Delaini, F, Oldani, E, Caprioli, C, Stefanoni, P, Gianfaldoni, G, Marmont, F, Ferrero, D, Terruzzi, E, De Paoli, L, Rossi, G, Borlenghi, E, Cavattoni, I, Tajana, M, Scattolin, Am, Mattei, D, Corradini, P, Campiotti, L, Ciceri, F, Bernardi, M, Todisco, E, Cortelezzi, A, Cortelazzo, S, Audisio, E, Bosi, A, Falini, B, Pavoni, C, Bassan, R, and Rambaldi, A

Published
2018

24. PF227 PROGNOSTIC VALUE OF CLONAL HEMATOPOIESIS-MUTATIONS DETECTED AT DIAGNOSIS IN ACUTE MYELOID LEUKEMIA PATIENTS WITH NORMAL KARYOTYPE

Author

Caprioli, C., primary, Spinelli, O., additional, Salmoiraghi, S., additional, Intermesoli, T., additional, Zanghì, P., additional, Cavagna, R., additional, Michelato, A., additional, Buklijas, K., additional, Elidi, L., additional, Delaini, F., additional, Oldani, E., additional, Gianfaldoni, G., additional, Bosi, A., additional, Marmont, F., additional, Audisio, E., additional, Ferrero, D., additional, Terruzzi, E., additional, De Paoli, L., additional, Rossi, G., additional, Borlenghi, E., additional, Cavattoni, I., additional, Tajana, M., additional, Scattolin, A.M., additional, Mattei, D., additional, Corradini, P., additional, Campiotti, L., additional, Ciceri, F., additional, Bernardi, M., additional, Todisco, E., additional, Cortelezzi, A., additional, Cortelazzo, S., additional, Falini, B., additional, Pavoni, C., additional, Bassan, R., additional, Rambaldi, A., additional, and Lussana, F., additional

Published
2019
Full Text
View/download PDF

25. PS1312 QPCR, MFC AND DDPCR: COMPARISON ON MRD SAMPLES FROM THREE PROSPECTIVE TRIALS OF THE EUROPEAN MCL NETWORK

Author

Drandi, D., primary, Alcantara, M., additional, Barbero, D., additional, Benmaad, I., additional, Lhermitte, L., additional, Ferrante, M., additional, Zaccaria, G.M., additional, Mantoan, B., additional, Genuardi, E., additional, Ruggeri, M., additional, Omedè, P., additional, Villarese, P., additional, Cheminant, M., additional, Cortelazzo, S., additional, Pott, C., additional, Dreyling, M., additional, Hermine, O., additional, Delfau-Larue, M.-H., additional, Ladetto, M., additional, Ferrero, S., additional, and Macintyre, E., additional

Published
2019
Full Text
View/download PDF

26. PS1248 COMPREHENSIVE ANALYSIS OF BASELINE OUTCOME BIOPREDICTORS IN YOUNGER PATIENTS WITH MANTLE CELL LYMPHOMA: THE ANCILLARY BIOLOGICAL STUDIES OF FONDAZIONE ITALIANA LINFOMI (FIL) MCL0208 CLINICAL TRIAL

Author

Ferrero, S., primary, Zaccaria, G.M., additional, Barbero, D., additional, Evangelista, A., additional, Rocco, A. Di, additional, Re, A., additional, Stefoni, V., additional, Cavallo, F., additional, Vitolo, U., additional, Balzarotti, M., additional, Rusconi, C., additional, da Silva, M. Gomes, additional, Ghislieri, M., additional, Omedè, P., additional, Zamò, A., additional, Ciccone, G., additional, Gattei, V., additional, Gaidano, G., additional, Cortelazzo, S., additional, and Ladetto, M., additional

Published
2019
Full Text
View/download PDF

29. Relevance of intraocular involvement in the management of primary central nervous system lymphomas

Author

Ferreri, A. J. M., Blay, J.-Y, Reni, M., Pasini, F., Gubkin, A., Tirelli, U., Calderoni, A., Zucca, E., Cortelazzo, S., Chassagne, C., Tinguely, M., Borisch, B., Berger, F., Ponzoni, M., Cavalli, F., Ferreri, A. J. M., Blay, J.-Y, Reni, M., Pasini, F., Gubkin, A., Tirelli, U., Calderoni, A., Zucca, E., Cortelazzo, S., Chassagne, C., Tinguely, M., Borisch, B., Berger, F., Ponzoni, M., and Cavalli, F.

Abstract

Background Reported data regarding intraocular lymphoma (IOL) management are anecdotal. Cases of IOL included in an international multicentre series of 378 immunocompetent patients with primary central nervous system lymphomas (PCNSLs) were reviewed. Patients and methods Staging included slit-lamp examination in 170 patients: IOL was diagnosed in 22 cases (13%). A concomitant brain lesion was detected in 21 cases. Planned treatment was chemotherapy followed by radiotherapy in 13 cases, chemotherapy alone in three and radiotherapy, followed by or not by chemotherapy in five; one patient was not treated. Chemotherapy included high-dose methotrexate in 12 cases. Ten patients received intrathecal chemotherapy. Radiotherapy consisted of whole brain irradiation, followed by or not by a tumour bed boost; ocular irradiation was planned in 15 cases. Irradiation in one patient without brain lesions was limited to the orbits only (50 Gy). Results IOL was positively correlated to systemic symptoms and meningeal disease. Fifteen patients (71%) achieved an objective response; 16 patients experienced a failure (2-year failure-free survival 34 ± 10%). Failures involved the eyes in eight cases, with a 2-year time to ocular relapse of 59 ± 11%. Ocular failure was less common in patients treated with chemotherapy plus ocular irradiation and was associated with a significantly shorter survival. Seven patients are alive [median follow-up 53 months, 2-year overall survival (OS): 39 ± 11%], five of whom were treated with ocular irradiation. The patient with isolated IOL is alive and disease-free at 14 months. OS of the entire series was similar to that of PCNSL patients with negative slit-lamp examination. Conclusions IOL is usually associated with concomitant brain disease and shows a survival similar to that of the rest of PCNSLs. Chemotherapy combined with ocular irradiation resulted in better control of ocular disease, which seems to be associated with survival. In view of the potenti

Published
2017

30. Role of radiotherapy in patients with early-stage diffuse large B-cell lymphoma of Waldeyer's ring in remission after anthracycline-containing chemotherapy

Author

Mian, M, Ferreri, A, Rossi, A, Conconi, A, Tsang, R, Gospodarowicz, M, Oldani, E, Federico, M, Luminari, S, Pogliani, E, Rossini, F, Cabrera, M, Martelli, M, Gutierrez Garcia, G, Busetto, M, Cavalli, F, Zucca, E, Rambaldi, A, Cortelazzo, S, ROSSI, ANDREA, POGLIANI, ENRICO MARIA, Cortelazzo, S., Mian, M, Ferreri, A, Rossi, A, Conconi, A, Tsang, R, Gospodarowicz, M, Oldani, E, Federico, M, Luminari, S, Pogliani, E, Rossini, F, Cabrera, M, Martelli, M, Gutierrez Garcia, G, Busetto, M, Cavalli, F, Zucca, E, Rambaldi, A, Cortelazzo, S, ROSSI, ANDREA, POGLIANI, ENRICO MARIA, and Cortelazzo, S.

Abstract

Consolidation radiotherapy (cRT) in patients with stage I/II diffuse large B-cell lymphoma of the Waldeyer's ring (WR-DLBCL) in complete remission (CR) after induction chemotherapy (CHT) is often associated with relevant acute and chronic toxicity, and its impact on survival remains to be defined. A total of 184 patients in CR after anthracycline-based chemotherapy were retrospectively analyzed: 62 underwent CHT alone (CHT group), while 122 (66%) patients were referred to cRT (CHT + RT group). After a median follow-up of 54 months, 36 patients (20%) experienced relapse: 19% in the CHT group and 20% in the CHT + RT group. At the time of analysis 47 (76%) CHT patients and 97 (80%) CHT + RT patients were alive. Five-year overall survival (OS), disease-free survival (DFS) and lymphoma-specific survival (LSS) were 80%, 74% and 86%, respectively. Five-year OS was significantly prolonged in the CHT + RT group, while DFS and LSS were similar between groups. This discrepancy was attributed to a high percentage of deaths due to unrelated causes in CHT patients. cRT does not prolong LSS in patients with early-stage WR-DLBCL in CR after anthracycline-containing chemotherapy. An international confirmatory trial is warranted.

Published
2013

31. KMT2D AND TP53 MUTATIONS PREDICT POOR PFS AND OS IN MANTLE CELL LYMPHOMA RECEIVING HIGH-DOSE THERAPY AND ASCT: THE FONDAZIONE ITALIANA LINFOMI (FIL) MCL0208 PHASE III TRIAL

Author

Ferrero, S., primary, Rossi, D., additional, Bruscaggin, A., additional, Evangelista, A., additional, Di Rocco, A., additional, Spina, V., additional, Stefoni, V., additional, Ghione, P., additional, Barbero, D., additional, Monitillo, L., additional, Gomes Da Silva, M., additional, Santoro, A., additional, Molinari, A., additional, Ferreri, A., additional, Piccin, A., additional, Cortelazzo, S., additional, Ladetto, M., additional, and Gaidano, G., additional

Published
2017
Full Text
View/download PDF

32. NOVEL MOLECULAR MARKERS FOR MINIMAL RESIDUAL DISEASE (MRD) MONITORING IN MANTLE CELL AND FOLLICULAR LYMPHOMA: THE TARGETED LOCUS AMPLIFICATION (TLA) NGS STRATEGY

Author

Ferrero, S., primary, Genuardi, E., additional, Klous, P., additional, Drandi, D., additional, Mantoan, B., additional, Monitillo, L., additional, Barbero, D., additional, Yilmaz, M., additional, Cattellino, F., additional, Vasta, M., additional, Cavallo, F., additional, Cortelazzo, S., additional, Vitolo, U., additional, Luminari, S., additional, Federico, M., additional, Boccadoro, M., additional, Splinter, E., additional, and Ladetto, M., additional

Published
2017
Full Text
View/download PDF

33. Bortezomib-thalidomide-dexamethasone is superior to thalidomide-dexamethasone as consolidation therapy after autologous hematopoietic stem cell transplantation in patients with newly diagnosed multiple myeloma

Author

Cavo, M, Pantani, L, Petrucci, M, Patriarca, F, Zamagni, E, Donnarumma, D, Crippa, C, Boccadoro, M, Perrone, G, Falcone, A, Nozzoli, C, Zambello, R, Masini, L, Furlan, A, Brioli, A, Derudas, D, Ballanti, S, Dessanti, M, De Stefano, V, Carella, A, Marcatti, M, Nozza, A, Ferrara, F, Callea, V, Califano, C, Pezzi, A, Baraldi, A, Grasso, M, Musto, P, Palumbo, A, Tosi, P, Motta, M, Rizzi, S, Fanin, R, Buttignol, S, Foà, R, Levi, A, Calabrese, E, Rambaldi, A, Galli, M, Rossi, G, Ferrari, S, Bringhen, S, Leoni, P, Offidani, M, Polloni, C, Corradini, P, Montefusco, V, Torelli, G, Narni, F, Fioritoni, G, Spadano, A, Cortelazzo, S, Pescosta, N, Billio, A, Lambertenghi Deliliers, G, Baldini, L, Onida, F, Annaloro, C, La Nasa, G, Ledda, A, Zaccaria, A, Cellini, C, De Fabritiis, P, Caravita, T, Siniscalchi, A, Cascavilla, N, Bosi, A, Semenzato, G, Gugliotta, L, Merli, F, Gherlinzoni, F, Angelucci, E, Martelli, M, Petti, M, Pisani, F, Leone, G, Rossi, E, Za, T, Fianchi, L, Catania, G, Spriano, M, Ciceri, F, Peccatori, J, Girlanda, S, Santoro, A, Castagna, L, Palmieri, S, Nobile, F, D'Arco, A, Levis, A, Primon, V, Tamiazzo, S, Guardigni, L, Pasini, S, Gallamini, A, Pietrantuono, G, Martorelli, M, Fattori, P, Pasquini, E, Galieni, P, Ruggieri, M, Morandi, S, Tajana, M, Amadori, D, Ronconi, S, Cangini, D, Ceccolini, M, Gobbi, M, Ballerini, F, Pane, F, Catalano, L, Cangialosi, C, Vallisa, D, Lazzaro, A, Paladini, G, De Sabbata, G, Mozzana, R, Ciambelli, F, Pinotti, G, Rodeghiero, F, Elice, F, Cantore, N, Volpe, S, Pavone, V, Mele, A, Pogliani, E, Rossini, F, Liberati, A, Majolino, I, De Rosa, L, Amadori, S, Rizzo, M, Lauria, F, Gozzetti, A, Aglietta, M, Capaldi, A, Quarta, G, Mele, G, Storti, S, Fraticelli, V, Morabito, F, Gentile, C, Capalbo, S, Gianni, A, Magni, M, Mettivier, V, Nunziata, G, Rizzoli, V, Giuliani, N, Crugnola, M, Bernasconi, C, Fregoni, V, Visani, G, Olivieri, A, Pizzuti, M, La Verde, G, Moscetti, A, Avvisati, G, Tirindelli, M, Longinotti, M, Podda, L, Gallo, E, Pregno, P, Dammacco, F, Perosa, F, Russo, D, Roccaro, A, Bacigalupo, A, Dominietto, A, Musolino, C, Quartarone, E, Tosi P, Motta MR, Rizzi S, Fanin R, Buttignol S, Foà R, Levi A, Calabrese E, Rambaldi A, Galli M, Rossi G, Ferrari S, Bringhen S, Leoni P, Offidani M, Polloni C, Corradini P, Montefusco V, Torelli G, Narni F, Fioritoni G, Spadano A, Cortelazzo S, Pescosta N, Billio A, Lambertenghi Deliliers G, Baldini L, Onida F, Annaloro C, La Nasa G, Ledda A, Zaccaria A, Cellini C, De Fabritiis P, Caravita T, Siniscalchi A, Cascavilla N, Bosi A, Semenzato G, Gugliotta L, Merli F, Gherlinzoni F, Angelucci E, Martelli M, Petti MC, Pisani F, Leone G, Rossi E, Za T, Fianchi L, Catania G, Spriano M, Ciceri F, Peccatori J, Girlanda S, Santoro A, Castagna L, Palmieri S, Nobile F, D'Arco AM, Levis A, Primon V, Tamiazzo S, Guardigni L, Pasini S, Gallamini A, Pietrantuono G, Martorelli MC, Fattori P, Pasquini E, Galieni P, Ruggieri M, Morandi S, Tajana M, Amadori D, Ronconi S, Cangini D, Ceccolini M, Gobbi M, Ballerini F, Pane F, Catalano L, Cangialosi C, Vallisa D, Lazzaro A, Paladini G, De Sabbata G, Mozzana R, Ciambelli F, Pinotti G, Rodeghiero F, Elice F, Cantore N, Volpe S, Pavone V, Mele A, POGLIANI, ENRICO MARIA, Rossini F, Liberati A, Majolino I, De Rosa L, Amadori S, Rizzo M, Lauria F, Gozzetti A, Aglietta M, Capaldi A, Quarta G, Mele G, Storti S, Fraticelli V, Morabito F, Gentile C, Capalbo S, Gianni A, Magni M, Mettivier V, Nunziata G, Rizzoli V, Giuliani N, Crugnola M, Bernasconi C, Fregoni V, Visani G, Olivieri A, Pizzuti M, La Verde G, Moscetti A, Avvisati G, Tirindelli M, Longinotti M, Podda L, Gallo E, Pregno P, Dammacco F, Perosa F, Russo D, Roccaro A, Bacigalupo A, Dominietto A, Musolino C, Quartarone E., Cavo, M, Pantani, L, Petrucci, M, Patriarca, F, Zamagni, E, Donnarumma, D, Crippa, C, Boccadoro, M, Perrone, G, Falcone, A, Nozzoli, C, Zambello, R, Masini, L, Furlan, A, Brioli, A, Derudas, D, Ballanti, S, Dessanti, M, De Stefano, V, Carella, A, Marcatti, M, Nozza, A, Ferrara, F, Callea, V, Califano, C, Pezzi, A, Baraldi, A, Grasso, M, Musto, P, Palumbo, A, Tosi, P, Motta, M, Rizzi, S, Fanin, R, Buttignol, S, Foà, R, Levi, A, Calabrese, E, Rambaldi, A, Galli, M, Rossi, G, Ferrari, S, Bringhen, S, Leoni, P, Offidani, M, Polloni, C, Corradini, P, Montefusco, V, Torelli, G, Narni, F, Fioritoni, G, Spadano, A, Cortelazzo, S, Pescosta, N, Billio, A, Lambertenghi Deliliers, G, Baldini, L, Onida, F, Annaloro, C, La Nasa, G, Ledda, A, Zaccaria, A, Cellini, C, De Fabritiis, P, Caravita, T, Siniscalchi, A, Cascavilla, N, Bosi, A, Semenzato, G, Gugliotta, L, Merli, F, Gherlinzoni, F, Angelucci, E, Martelli, M, Petti, M, Pisani, F, Leone, G, Rossi, E, Za, T, Fianchi, L, Catania, G, Spriano, M, Ciceri, F, Peccatori, J, Girlanda, S, Santoro, A, Castagna, L, Palmieri, S, Nobile, F, D'Arco, A, Levis, A, Primon, V, Tamiazzo, S, Guardigni, L, Pasini, S, Gallamini, A, Pietrantuono, G, Martorelli, M, Fattori, P, Pasquini, E, Galieni, P, Ruggieri, M, Morandi, S, Tajana, M, Amadori, D, Ronconi, S, Cangini, D, Ceccolini, M, Gobbi, M, Ballerini, F, Pane, F, Catalano, L, Cangialosi, C, Vallisa, D, Lazzaro, A, Paladini, G, De Sabbata, G, Mozzana, R, Ciambelli, F, Pinotti, G, Rodeghiero, F, Elice, F, Cantore, N, Volpe, S, Pavone, V, Mele, A, Pogliani, E, Rossini, F, Liberati, A, Majolino, I, De Rosa, L, Amadori, S, Rizzo, M, Lauria, F, Gozzetti, A, Aglietta, M, Capaldi, A, Quarta, G, Mele, G, Storti, S, Fraticelli, V, Morabito, F, Gentile, C, Capalbo, S, Gianni, A, Magni, M, Mettivier, V, Nunziata, G, Rizzoli, V, Giuliani, N, Crugnola, M, Bernasconi, C, Fregoni, V, Visani, G, Olivieri, A, Pizzuti, M, La Verde, G, Moscetti, A, Avvisati, G, Tirindelli, M, Longinotti, M, Podda, L, Gallo, E, Pregno, P, Dammacco, F, Perosa, F, Russo, D, Roccaro, A, Bacigalupo, A, Dominietto, A, Musolino, C, Quartarone, E, Tosi P, Motta MR, Rizzi S, Fanin R, Buttignol S, Foà R, Levi A, Calabrese E, Rambaldi A, Galli M, Rossi G, Ferrari S, Bringhen S, Leoni P, Offidani M, Polloni C, Corradini P, Montefusco V, Torelli G, Narni F, Fioritoni G, Spadano A, Cortelazzo S, Pescosta N, Billio A, Lambertenghi Deliliers G, Baldini L, Onida F, Annaloro C, La Nasa G, Ledda A, Zaccaria A, Cellini C, De Fabritiis P, Caravita T, Siniscalchi A, Cascavilla N, Bosi A, Semenzato G, Gugliotta L, Merli F, Gherlinzoni F, Angelucci E, Martelli M, Petti MC, Pisani F, Leone G, Rossi E, Za T, Fianchi L, Catania G, Spriano M, Ciceri F, Peccatori J, Girlanda S, Santoro A, Castagna L, Palmieri S, Nobile F, D'Arco AM, Levis A, Primon V, Tamiazzo S, Guardigni L, Pasini S, Gallamini A, Pietrantuono G, Martorelli MC, Fattori P, Pasquini E, Galieni P, Ruggieri M, Morandi S, Tajana M, Amadori D, Ronconi S, Cangini D, Ceccolini M, Gobbi M, Ballerini F, Pane F, Catalano L, Cangialosi C, Vallisa D, Lazzaro A, Paladini G, De Sabbata G, Mozzana R, Ciambelli F, Pinotti G, Rodeghiero F, Elice F, Cantore N, Volpe S, Pavone V, Mele A, POGLIANI, ENRICO MARIA, Rossini F, Liberati A, Majolino I, De Rosa L, Amadori S, Rizzo M, Lauria F, Gozzetti A, Aglietta M, Capaldi A, Quarta G, Mele G, Storti S, Fraticelli V, Morabito F, Gentile C, Capalbo S, Gianni A, Magni M, Mettivier V, Nunziata G, Rizzoli V, Giuliani N, Crugnola M, Bernasconi C, Fregoni V, Visani G, Olivieri A, Pizzuti M, La Verde G, Moscetti A, Avvisati G, Tirindelli M, Longinotti M, Podda L, Gallo E, Pregno P, Dammacco F, Perosa F, Russo D, Roccaro A, Bacigalupo A, Dominietto A, Musolino C, and Quartarone E.

Abstract

In a randomized, phase 3 study, superior complete/near-complete response (CR/nCR) rates and extended progression-free survival were demonstrated with bortezomib-thalidomide-dexamethasone (VTD) versus thalidomide-dexamethasone (TD) as induction therapy before, and consolidation after, double autologous stem cell transplantation for newly diagnosed myeloma patients (intention-to-treat analysis; VTD, n = 236; TD, n = 238). This per-protocol analysis (VTD, n = 160; TD, n = 161) specifically assessed the efficacy and safety of consolidation with VTD or TD. Before starting consolidation, CR/nCR rates were not significantly different in the VTD (63.1%) and TD arms (54.7%). After consolidation, CR (60.6% vs 46.6%) and CR/nCR (73.1% vs 60.9%) rates were significantly higher for VTD-treated versus TD-treated patients. VTD consolidation significantly increased CR and CR/nCR rates, but TD did not (McNemar test). With a median follow-up of 30.4 months from start of consolidation, 3-year progression-free survival was significantly longer for the VTD group (60% vs 48% for TD). Grade 2 or 3 peripheral neuropathy (8.1% vs 2.4%) was more frequent with VTD (grade 3, 0.6%) versus TD consolidation. The superior efficacy of VTD versus TD as induction was retained despite readministration as consolidation therapy after double autologous transplantation. VTD consolidation therapy significantly contributed to improved clinical outcomes observed for patients randomly assigned to the VTD arm of the study. The study is registered at www.clinicaltrials.gov as #NCT01134484.

Published
2012

35. CLIPI: a new prognostic index for indolent cutaneous B cell lymphoma proposed by the International Extranodal Lymphoma Study Group (IELSG 11)

Author

Mian, M, Marcheselli, L, Luminari, S, Federico, M, Cantonetti, M, Sarris, A, Rossi, A, Rambaldi, A, Frontani, M, Devizzi, L, Gianni, A, Busetto, M, Berti, E, Martinelli, G, Tsang, R, Ferreri, A, Pinotti, G, Pogliani, E, Zucca, E, Cortelazzo, S, Sarris, AH, Gianni, AM, BERTI, EMILIO, Tsang, RW, Ferreri, AJM, POGLIANI, ENRICO MARIA, Cortelazzo, S., Mian, M, Marcheselli, L, Luminari, S, Federico, M, Cantonetti, M, Sarris, A, Rossi, A, Rambaldi, A, Frontani, M, Devizzi, L, Gianni, A, Busetto, M, Berti, E, Martinelli, G, Tsang, R, Ferreri, A, Pinotti, G, Pogliani, E, Zucca, E, Cortelazzo, S, Sarris, AH, Gianni, AM, BERTI, EMILIO, Tsang, RW, Ferreri, AJM, POGLIANI, ENRICO MARIA, and Cortelazzo, S.

Abstract

Indolent primary cutaneous B cell lymphomas (PCBCL) generally have a good prognosis, but they often relapse leading in some cases to extracutaneous disease and therefore, to poor survival. We developed a prognostic model to improve the therapeutic approach to these lymphomas. Two hundred and seventeen patients with diagnosis of indolent PCBCL stage IE or IIE were assessed retrospectively. The prognostic model was built to fit a Cox proportional hazard model using all the covariates affecting progression-free survival (PFS) at p<0.1 in the univariate analysis, and the final model was selected based on the Bayes Information Criteria. Elevated serum lactate dehydrogenase, morphology of the lesion (nodule vs. other), and >2 lesions were independent predictors for PFS. To each prognostic factor was assigned a value of 1. Patients were then stratified to three risk groups: score 0 (28%), low risk; score 1 (55%), intermediate risk; score 2 and 3 (17%), high risk with a 5-year PFS of 91%, 64%, and 48%, respectively (p<0.001). The CLIPI is an easily applicable prognostic index and represents a promising tool for risk-adapted treatment strategies. However, it needs to be addressed in prospective clinical studies.

Published
2011

36. High response rate and improvement of long-term survival with combined treatment modalities in patients with poor-risk primary thyroid diffuse large B-cell lymphoma: an International Extranodal Lymphoma Study Group and Intergruppo Italiano Linfomi study

Author

Mian, M, Gaidano, G, Conconi, A, Tsang, R, Gospodarowicz, M, Rambaldi, A, Rossi, A, Oldani, E, Federico, M, Luminari, S, Bellei, M, Pogliani, E, Rossini, F, Cabrera, M, Martelli, M, Lopez Guillermo, A, Busetto, M, Cavalli, F, Zucca, E, Cortelazzo, S, Gospodarowicz, MK, POGLIANI, ENRICO MARIA, Cabrera, ME, Cortelazzo, S., Mian, M, Gaidano, G, Conconi, A, Tsang, R, Gospodarowicz, M, Rambaldi, A, Rossi, A, Oldani, E, Federico, M, Luminari, S, Bellei, M, Pogliani, E, Rossini, F, Cabrera, M, Martelli, M, Lopez Guillermo, A, Busetto, M, Cavalli, F, Zucca, E, Cortelazzo, S, Gospodarowicz, MK, POGLIANI, ENRICO MARIA, Cabrera, ME, and Cortelazzo, S.

Abstract

The impact of different treatment modalities and prognostic factors on the clinical course of primary thyroid diffuse large B-cell lymphoma (PTDLBCL) is still the subject of research. This study was conducted to clarify these clinical aspects of this disorder. The clinical parameters of 48 patients with PTDLBCL at time of diagnosis were comparable to those of previous studies. Patients underwent either radiotherapy (RT) ±° surgery (SX), chemotherapy (CHT) alone or in combination with local treatments (RT or SX), or SX followed by CHT and RT. A 90% complete remission (CR) rate was observed among patients who underwent combined treatment modalities (CTM), compared to 76% among the others. The 5-year progression-free survival differed significantly between both groups (p = 0.028). Poor performance status and advanced age correlated with decreased survival. PTDLBCL is a curable disease prevalent in elderly patients. Combined treatment modalities were able to induce an elevated rate of CR, improving long-term survival in younger patients. However, the outcome in elderly patients still remains unsatisfactory. © 2011 Informa UK, Ltd.

Published
2011

37. Treosulfan-fludarabine-ATG-F based reduced-toxicity conditioning regimen: multicentre 'Allo-Treo' study, results in 183 patients with haematological malignancies

Author

Crotta A, Lorusso A, Martinelli G, Cortelazzo S, Pinazzi MB, La Nasa G, Foa R, Santarone S, Rambaldi A, Gallamini A, Fanin R, Merli F, Carella AM, Corti C, Ruggeri A, Marcatti M, Stanghellini MTL, Assanelli A, Messina C, Bernardi M, Peccatori J., CICERI , FABIO, Crotta, A, Lorusso, A, Martinelli, G, Cortelazzo, S, Pinazzi, Mb, La Nasa, G, Foa, R, Santarone, S, Rambaldi, A, Gallamini, A, Fanin, R, Merli, F, Carella, Am, Corti, C, Ruggeri, A, Marcatti, M, Stanghellini, Mtl, Assanelli, A, Messina, C, Bernardi, M, Ciceri, Fabio, and Peccatori, J.

Published
2012

38. Bortezomib-thalidomide-dexamethasone is superior to thalidomide-dexamethasone as consolidation therapy following autologous hematopoietic stem-cell transplantation in patients with newly diagnosed multiple myeloma

Author

Cavo, Michele, Pantani, Lucia, Petrucci, Maria Teresa, Patriarca, Francesca, Zamagni, Elena, Donnarumma, Daniela, Crippa, Claudia, Boccadoro, Mario, Perrone, Giulia, Falcone, Antonietta, Nozzoli, Chiara, Zambello, Renato, Masini, Luciano, Furlan, Anna, Brioli, Annamaria, Derudas, Daniele, Ballanti, Stelvio, Dessanti, Maria Laura, De Stefano, Valerio, Carella, Angelo Michele, Marcatti, Magda, Nozza, Andrea, Ferrara, Felicetto, Callea, Vincenzo, Califano, Catello, Pezzi, Annalisa, Baraldi, Anna, Grasso, Mariella, Musto, Pellegrino, Palumbo, Antonio COLLABORATORI: Tosi, P, Motta, Mr, Rizzi, S, Fanin, R, Buttignol, S, Foà, R, Levi, A, Calabrese, E, Rambaldi, A, Galli, M, Rossi, G, Ferrari, S, Bringhen, S, Leoni, P, Offidani, M, Polloni, C, Corradini, P, Montefusco, V, Torelli, G, Narni, Franco, Fioritoni, G, Spadano, A, Cortelazzo, S, Pescosta, N, Billio, A, Lambertenghi Deliliers, G, Baldini, L, Onida, F, Annaloro, C, La Nasa, G, Ledda, A, Zaccaria, A, Cellini, C, De Fabritiis, P, Caravita, T, Siniscalchi, A, Cascavilla, N, Bosi, A, Semenzato, G, Gugliotta, L, Merli, F, Gherlinzoni, F, Angelucci, E, Martelli, M, Petti, Mc, Pisani, F, Leone, G, Rossi, E, Za, T, Fianchi, L, Catania, G, Spriano, M, Ciceri, F, Peccatori, J, Girlanda, S, Santoro, A, Castagna, L, Palmieri, S, Nobile, F, D'Arco, Am, Levis, A, Primon, V, Tamiazzo, S, Guardigni, L, Pasini, S, Gallamini, A, Pietrantuono, G, Martorelli, Mc, Fattori, P, Pasquini, E, Galieni, P, Ruggieri, M, Morandi, S, Tajana, M, Amadori, D, Ronconi, S, Cangini, D, Ceccolini, M, Gobbi, M, Ballerini, F, Pane, F, Catalano, L, Cangialosi, C, Vallisa, D, Lazzaro, A, Paladini, G, De Sabbata, G, Mozzana, R, Ciambelli, F, Pinotti, G, Rodeghiero, F, Elice, F, Cantore, N, Volpe, S, Pavone, V, Mele, A, Pogliani, E, Rossini, F, Liberati, A, Majolino, I, De Rosa, L, Amadori, S, Rizzo, M, Lauria, F, Gozzetti, A, Aglietta, M, Capaldi, A, Quarta, G, Mele, G, Storti, S, Fraticelli, V, Morabito, F, Gentile, C, Capalbo, S, Gianni, A, Magni, M, Mettivier, V, Nunziata, G, Rizzoli, V, Giuliani, N, Crugnola, M, Bernasconi, C, Fregoni, V, Visani, G, Olivieri, A, Pizzuti, M, La Verde, G, Moscetti, A, Avvisati, G, Tirindelli, M, Longinotti, M, Podda, L, Gallo, E, Pregno, P, Dammacco, F, Perosa, F, Russo, D, Roccaro, A, Bacigalupo, A, Dominietto, A, Musolino, C, Quartarone, E., Cavo M, Pantani L, Petrucci MT, Patriarca F, Zamagni E, Donnarumma D, Crippa C, Boccadoro M, Perrone G, Falcone A, Nozzoli C, Zambello R, Masini L, Furlan A, Brioli A, Derudas D, Ballanti S, Dessanti ML, De Stefano V, Carella AM, Marcatti M, Nozza A, Ferrara F, Callea V, Califano C, Pezzi A, Baraldi A, Grasso M, Musto P, Palumbo A., Cavo, Michele, Pantani, Lucia, Petrucci, Maria Teresa, Patriarca, Francesca, Zamagni, Elena, Donnarumma, Daniela, Crippa, Claudia, Boccadoro, Mario, Perrone, Giulia, Falcone, Antonietta, Nozzoli, Chiara, Zambello, Renato, Masini, Luciano, Furlan, Anna, Brioli, Annamaria, Derudas, Daniele, Ballanti, Stelvio, Dessanti, Maria Laura, De Stefano, Valerio, Carella, Angelo Michele, Marcatti, Magda, Nozza, Andrea, Ferrara, Felicetto, Callea, Vincenzo, Califano, Catello, Pezzi, Annalisa, Baraldi, Anna, Grasso, Mariella, Musto, Pellegrino, Palumbo, Antonio, Cavo, M, Pantani, L, Petrucci, M, Patriarca, F, Zamagni, E, Donnarumma, D, Crippa, C, Boccadoro, M, Perrone, G, Falcone, A, Nozzoli, C, Zambello, R, Masini, L, Furlan, A, Brioli, A, Derudas, D, Ballanti, S, Dessanti, M, De Stefano, V, Carella, A, Marcatti, M, Nozza, A, Ferrara, F, Callea, V, Califano, C, Pezzi, A, Baraldi, A, Grasso, M, Musto, P, Palumbo, A, Tosi, P, Motta, M, Rizzi, S, Fanin, R, Buttignol, S, Foà, R, Levi, A, Calabrese, E, Rambaldi, A, Galli, M, Rossi, G, Ferrari, S, Bringhen, S, Leoni, P, Offidani, M, Polloni, C, Corradini, P, Montefusco, V, Torelli, G, Narni, F, Fioritoni, G, Spadano, A, Cortelazzo, S, Pescosta, N, Billio, A, Lambertenghi Deliliers, G, Baldini, L, Onida, F, Annaloro, C, La Nasa, G, Ledda, A, Zaccaria, A, Cellini, C, De Fabritiis, P, Caravita, T, Siniscalchi, A, Cascavilla, N, Bosi, A, Semenzato, G, Gugliotta, L, Merli, F, Gherlinzoni, F, Angelucci, E, Martelli, M, Petti, M, Pisani, F, Leone, G, Rossi, E, Za, T, Fianchi, L, Catania, G, Spriano, M, Ciceri, F, Peccatori, J, Girlanda, S, Santoro, A, Castagna, L, Palmieri, S, Nobile, F, D'Arco, A, Levis, A, Primon, V, Tamiazzo, S, Guardigni, L, Pasini, S, Gallamini, A, Pietrantuono, G, Martorelli, M, Fattori, P, Pasquini, E, Galieni, P, Ruggieri, M, Morandi, S, Tajana, M, Amadori, D, Ronconi, S, Cangini, D, Ceccolini, M, Gobbi, M, Ballerini, F, Pane, F, Catalano, L, Cangialosi, C, Vallisa, D, Lazzaro, A, Paladini, G, De Sabbata, G, Mozzana, R, Ciambelli, F, Pinotti, G, Rodeghiero, F, Elice, F, Cantore, N, Volpe, S, Pavone, V, Mele, A, Pogliani, E, Rossini, F, Liberati, A, Majolino, I, De Rosa, L, Amadori, S, Rizzo, M, Lauria, F, Gozzetti, A, Aglietta, M, Capaldi, A, Quarta, G, Mele, G, Storti, S, Fraticelli, V, Morabito, F, Gentile, C, Capalbo, S, Gianni, A, Magni, M, Mettivier, V, Nunziata, G, Rizzoli, V, Giuliani, N, Crugnola, M, Bernasconi, C, Fregoni, V, Visani, G, Olivieri, A, Pizzuti, M, La Verde, G, Moscetti, A, Avvisati, G, Tirindelli, M, Longinotti, M, Podda, L, Gallo, E, Pregno, P, Dammacco, F, Perosa, F, Russo, D, Roccaro, A, Bacigalupo, A, Dominietto, A, Musolino, C, and Quartarone, E

Subjects
Male, Boronic Acid, medicine.medical_treatment, PLUS DEXAMETHASONE, Phases of clinical research, Kaplan-Meier Estimate, Hematopoietic stem cell transplantation, Biochemistry, Antineoplastic Agent, Bortezomib-thalidomide-dexamethasone, Bortezomib, Immunosuppressive Agent, Autologous stem-cell transplantation, MULTIPLE MYELOMA, Antineoplastic Combined Chemotherapy Protocols, thalidomide-dexamethasone, Multiple myeloma, RANDOMIZED PHASE-3, LENALIDOMIDE, STEM CELL TRANSPLANTATION, Hematopoietic Stem Cell Transplantation, PHASE-III TRIAL, Hematology, Middle Aged, CHEMOTHERAPY, Prognosis, Boronic Acids, Combined Modality Therapy, Thalidomide, Transplantation, Autologou, Pyrazines, HIGH-DOSE MELPHALAN, INDUCTION TREATMENT, Female, Autologous, Immunosuppressive Agents, Pyrazine, Human, medicine.drug, MAINTENANCE THERAPY, medicine.medical_specialty, DOXORUBICIN, Antineoplastic Agents, Hormonal, Prognosi, Immunology, Urology, Antineoplastic Agents, dexamethasone, Transplantation, Autologous, Disease-Free Survival, Dexamethasone, Humans, Multiple Myeloma, Cell Biology, medicine, Autologous transplantation, METAANALYSIS, Transplantation, Antineoplastic Combined Chemotherapy Protocol, Hormonal, business.industry, medicine.disease, Surgery, business, Settore MED/15 - Malattie del Sangue
Abstract

In a randomized, phase 3 study, superior complete/near-complete response (CR/nCR) rates and extended progression-free survival were demonstrated with bortezomib-thalidomide-dexamethasone (VTD) versus thalidomide-dexamethasone (TD) as induction therapy before, and consolidation after, double autologous stem cell transplantation for newly diagnosed myeloma patients (intention-to-treat analysis; VTD, n = 236; TD, n = 238). This per-protocol analysis (VTD, n = 160; TD, n = 161) specifically assessed the efficacy and safety of consolidation with VTD or TD. Before starting consolidation, CR/nCR rates were not significantly different in the VTD (63.1%) and TD arms (54.7%). After consolidation, CR (60.6% vs 46.6%) and CR/nCR (73.1% vs 60.9%) rates were significantly higher for VTD-treated versus TD-treated patients. VTD consolidation significantly increased CR and CR/nCR rates, but TD did not (McNemar test). With a median follow-up of 30.4 months from start of consolidation, 3-year progression-free survival was significantly longer for the VTD group (60% vs 48% for TD). Grade 2 or 3 peripheral neuropathy (8.1% vs 2.4%) was more frequent with VTD (grade 3, 0.6%) versus TD consolidation. The superior efficacy of VTD versus TD as induction was retained despite readministration as consolidation therapy after double autologous transplantation. VTD consolidation therapy significantly contributed to improved clinical outcomes observed for patients randomly assigned to the VTD arm of the study. The study is registered at www.clinicaltrials.gov as #NCT01134484.

Published
2012

40. High-dose sequential chemoimmunotherapy supported by autologous stem cell transplantation in patients with systemic B-cell lymphoma and central nervous system involvement: interim analysis of a multicentre phase II Trial

Author

Marturano E, Patti C, Cabras MG, Cortelazzo S, Zambello R, Carrabba M, Mule A, Peccatori J, Tarella C, Ferreri AJ, CICERI , FABIO, Marturano, E, Patti, C, Cabras, Mg, Cortelazzo, S, Zambello, R, Carrabba, M, Mule, A, Peccatori, J, Ciceri, Fabio, Tarella, C, and Ferreri, Aj

Published
2011

41. Factors influencing the occurrence of secondary malignancies in high-risk lymphoma patients following high-dose therapy and autograft

Author

Tarella C, Passera R, Magni M, Rossi A, Benedetti F, Gueli A, Ruella M, Patti C, Parvis G, Gallamini A, Cortelazzo S, Corradini P, Zoli V, Mule A, Crocchiolo R, Bosa M, Barbui A, Di Nicola M, Caracciolo D, Sorio M, Gianni AM, Rambaldi A., CICERI , FABIO, Tarella, C, Passera, R, Magni, M, Rossi, A, Benedetti, F, Gueli, A, Ruella, M, Patti, C, Parvis, G, Ciceri, Fabio, Gallamini, A, Cortelazzo, S, Corradini, P, Zoli, V, Mule, A, Crocchiolo, R, Bosa, M, Barbui, A, Di Nicola, M, Caracciolo, D, Sorio, M, Gianni, Am, and Rambaldi, A.

Published
2010

42. Allogeneic Stem Cell Transplantation (Allo-SCT) Following a Reduced-Intensity Conditioning (RIC) Regimen in Relapsed Peripheral T-Cell Lymphomas (PTCL): Results at 4 Year of Median Follow-up

Author

Dodero A, Spina F, Nami F, Patriarca F, Cortelazzo S, Benedetti F, CICERI , FABIO, Baronciani D, Scime' R, Pogliani E, Rambaldi A, Bonifazi F, Olivieri A, Bruno B, Tarella C, Corradini P., Dodero, A, Spina, F, Nami, F, Patriarca, F, Cortelazzo, S, Benedetti, F, Ciceri, Fabio, Baronciani, D, Scime', R, Pogliani, E, Rambaldi, A, Bonifazi, F, Olivieri, A, Bruno, B, Tarella, C, and Corradini, P.

Published
2009

43. ANTRACYCLINE BASED CHEMOTHERAPY AS PRIMARY TREATMENT FOR INTRAVASCULAR LYMPHOMA

Author

Ferreri, A, Campo, E, Ambrosetti, A, Ilariucci, F, Seymour, J, Willemze, R, Arrigoni, G, Rossi, G, LOPEZ GUILLERMO, A, Berti, E, Eriksson, M, Federico, M, Cortelazzo, S, Govi, S, Frungillo, N, Dell'Oro, S, Lestani, M, Asioli, S, Pedrinis, E, Ungari, M, Motta, T, Rossi, R, Artusi, T, Izzulino, P, Zucca, E, Cavalli, F, Ponzoni, M, FERRERI, A, CAMPO, E, AMBROSETTI, A, ILARIUCCI, F, SEYMOUR, J, WILLEMZE, R, ARRIGONI, G, ROSSI, G, ERIKSSON, M, FEDERICO, M, CORTELAZZO, S, GOVI, S, FRUNGILLO, N, DELL'ORO, S, LESTANI, M, ASIOLI, S, PEDRINIS, E, UNGARI, M, MOTTA, T, ROSSI, R, ARTUSI, T, IZZULINO, P, ZUCCA, E, CAVALLI, F, PONZONI, M., BERTI, EMILIO, Ferreri, A, Campo, E, Ambrosetti, A, Ilariucci, F, Seymour, J, Willemze, R, Arrigoni, G, Rossi, G, LOPEZ GUILLERMO, A, Berti, E, Eriksson, M, Federico, M, Cortelazzo, S, Govi, S, Frungillo, N, Dell'Oro, S, Lestani, M, Asioli, S, Pedrinis, E, Ungari, M, Motta, T, Rossi, R, Artusi, T, Izzulino, P, Zucca, E, Cavalli, F, Ponzoni, M, FERRERI, A, CAMPO, E, AMBROSETTI, A, ILARIUCCI, F, SEYMOUR, J, WILLEMZE, R, ARRIGONI, G, ROSSI, G, ERIKSSON, M, FEDERICO, M, CORTELAZZO, S, GOVI, S, FRUNGILLO, N, DELL'ORO, S, LESTANI, M, ASIOLI, S, PEDRINIS, E, UNGARI, M, MOTTA, T, ROSSI, R, ARTUSI, T, IZZULINO, P, ZUCCA, E, CAVALLI, F, PONZONI, M., and BERTI, EMILIO

Abstract

Background: Optimal therapeutic management of intravascular lymphoma (IVL) lacks precise guidelines. Patients and methods: The clinico-pathological features of 38 HIV-negative patients with IVL were reviewed to define efficacy of chemotherapy in these malignancies. Clinical characteristics of 22 patients treated with chemotherapy and of 16 untreated patients were compared in order to understand better the impact and causes of potential patient selection. Results: Median age was 70 years (range 34-90), with a male/female ratio of 0.9; 23 (61%) patients had Eastern Cooperative Oncology Group performance status (ECOG-PS) >1; 21 (55%) had systemic symptoms. Cutaneous lesions and anemia were significantly more common among patients treated with chemotherapy; central nervous system (CNS) and renal involvement were significantly more common among untreated patients. Chemotherapy was associated with a response rate of 59% and a 3-year overall survival of 33 ± 11%. Five of six patients with CNS involvement received chemotherapy: four of them died early; only one patient, treated with adriamycin, cyclophosphamide, vincristine, methotrexate, bleomycin and prednisolone (MACOP-B) followed by high-dose chemotherapy and autologous stem cell transplantation (ASCT), was alive at 19 months. High-dose chemotherapy supported by ASCT was indicated at diagnosis in another patient (43 years of age, stage I), who was alive at 71 months, and at relapse after cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP) in two patients who died early after transplantation. PS ≤1, disease limited to the skin, stage I, and use of chemotherapy were independently associated with better outcome. Conclusions: Anthracycline-based chemotherapy is the standard treatment for IVL. However, survival is disappointing, with a relevant impact of diagnostic delay and lethal complications. More intensive combinations, containing drugs with higher CNS bioavailability, are needed in cases with brain involve

Published
2004

44. TIME OF PERIPHERAL BLOOD PROGENITOR CELL COLLECTIONS MAY INFLUENCE THE RISK OF SECONDARY MYELODYSPLASTIC SYNDROME/ACUTE LEUKEMIA FOLLOWING INTENSIVE THERAPY AND AUTOGRAFT: A GITIL SURVEY ON 1,347 LYMPHOMA PATIENTS RECEIVING THE HIGH-DOSE SEQUENTIAL PROGRAM

Author

Tarella C, Zanni M, Magni M, Rossi A, Benedetti F, Passera R, Patti C, Parvis G, Gallamini A, Cortelazzo S, Majolino I, Barbui T, Mirto S, Corradini P, Boccadoro M, Saglio G, Pizzolo G, Rambaldi A, Gianni AM, CICERI , FABIO, Tarella, C, Zanni, M, Magni, M, Rossi, A, Benedetti, F, Passera, R, Patti, C, Parvis, G, Ciceri, Fabio, Gallamini, A, Cortelazzo, S, Majolino, I, Barbui, T, Mirto, S, Corradini, P, Boccadoro, M, Saglio, G, Pizzolo, G, Rambaldi, A, and Gianni, Am

Published
2008

45. Prospective, multicenter randomized GITMO/IIL trial comparing intensive (R-HDS) versus conventional (CHOP-R) chemoimmunotherapy in high-risk follicular lymphoma at diagnosis: the superior disease control of R-HDS does not translate into an overall survival advantage

Author

Ladetto, M, DE MARCO, F, Benedetti, F, Vitolo, U, Patti, C, Rambaldi, A, Pulsoni, Alessandro, Musso, M, Liberati, Am, Olivieri, A, Gallamini, A, Pogliani, E, Scalabrini, Dr, Callea, V, DI RAIMONDO, F, Pavone, V, Tucci, A, Cortelazzo, S, Levis, A, Boccadoro, M, Majolino, I, Pileri, A, Gianni, Am, Passera, R, Corradini, P, Tarella, C, GRUPPO ITALIANO TRAPIANTO DI MIDOLLO OSSEO GITMO, INTERGRUPPO ITALIANO LINFOMI IIL, Foa, Roberto, Ladetto, M, De Marco, F, Benedetti, F, Vitolo, U, Patti, C, Rambaldi, A, Pulsoni, A, Musso, M, Liberati, A, Olivieri, A, Gallamini, A, Pogliani, E, Scalabrini, D, Callea, V, Di Raimondo, F, Pavone, V, Tucci, A, Cortelazzo, S, Levis, A, Boccadoro, M, Majolino, I, Pileri, A, Gianni, A, Passera, R, Corradini, P, and Tarella, C

Subjects
Male, Lymphoma, Follicular lymphoma, Salvage therapy, PREDICTIVE MODEL, Kaplan-Meier Estimate, INDOLENT LYMPHOMA, CHOP, Biochemistry, Gastroenterology, Antibodies, Monoclonal, Murine-Derived, Risk Factors, MED/15 - MALATTIE DEL SANGUE, hemic and lymphatic diseases, BONE-MARROW-TRANSPLANTATION, TERM-FOLLOW-UP, DOSE SEQUENTIAL CHEMOTHERAPY, STEM-CELL TRANSPLANTATION, NON-HODGKINS-LYMPHOMA, PROGRESSION-FREE SURVIVAL, MINIMAL RESIDUAL DISEASE, UNTREATED PATIENTS, Antineoplastic Combined Chemotherapy Protocols, Clinical endpoint, Medicine, Prospective Studies, Treatment Failure, Lymphoma, Follicular, Antibodies, Monoclonal, Hematology, Middle Aged, Rituximab, prognosis, Transplantation, Autologou, Treatment Outcome, Female, Survival Analysi, Immunotherapy, medicine.drug, Human, Adult, medicine.medical_specialty, Adolescent, Immunology, Transplantation, Autologous, Chemoimmunotherapy, Internal medicine, Humans, Proportional Hazards Models, Salvage Therapy, Antineoplastic Combined Chemotherapy Protocol, business.industry, Risk Factor, Cell Biology, Phosphamide, medicine.disease, Survival Analysis, Surgery, Transplantation, Feasibility Studie, Prospective Studie, Proportional Hazards Model, Feasibility Studies, business
Abstract

In this randomized multicenter study of 136 patients, 6 courses of CHOP (cyclo-phosphamide/doxorubicin/vincristine/prednisone) followed by rituximab (CHOP-R) were compared with rituximab-supplemented high-dose sequential chemotherapy with autografting (R-HDS) to assess the value of intensified chemo-therapy as a first-line treatment for high-risk follicular lymphoma (FL) after the introduction of monoclonal antibodies. The analysis was intention to treat with event-free survival (EFS) as the primary endpoint. Complete remission (CR) was 62% with CHOP-R and 85% with R-HDS (P < .001). At a median follow-up (MFU) of 51 months, the 4-year EFS was 28% and 61%, respectively (P < .001), with no difference in overall survival (OS). Molecular remission (MR) was achieved in 44% of CHOP-R and 80% of R-HDS patients (P < .001), and was the strongest independent outcome predictor. Patients relapsing after CHOP-R underwent salvage R-HDS in 71% of cases. Salvage R-HDS had an 85% CR rate and a 68% 3-year EFS (MFU, 30 months). We conclude that (1) achieving MR is critical for effective disease control, regardless of which treatment is used; (2) R-HDS ensures superior disease control and molecular outcome than CHOP-R, but no OS improvement; and (3) CHOP-R failures have a good outcome after salvage R-HDS, suggesting that relapsed/refractory FL could be the most appropriate setting for R-HDS–like treatments. This trial was registered at www.clinicaltrials.gov as no. NCT00435955.

Published
2008

46. Update of a GITIL cohort study: Frontline high dose sequential chemotherapy with rituximab and autologous stem cell transplantation induces a high rate of long-term remissions in patients with mantle cell lymphoma

Author

Cortelazzo S, Magni M, Tarella C, Mian M, Billio A, Rossi A, Marchesi M, Gallamini A, Corradini P, Parvis G, Majolino I, Patti C, Mirto S, Benedetti F, Pizzolo G, Gianni AM, Rambaldi A., CICERI , FABIO, Cortelazzo, S, Magni, M, Tarella, C, Mian, M, Billio, A, Rossi, A, Marchesi, M, Gallamini, A, Corradini, P, Ciceri, Fabio, Parvis, G, Majolino, I, Patti, C, Mirto, S, Benedetti, F, Pizzolo, G, Gianni, Am, and Rambaldi, A.

Published
2007

47. The risk of secondary myelodysplastic syndrome/acute leukemia following intensive therapy and autograft correlates with the type of cells grafted: A survey on 1,347 lymphoma patients receiving the high-dose sequential (HDS) program

Author

Zanni M, Magni M, Rambaldi A, Benedetti F, Passera R, Patti C, Parvis G, Gallamini A, Cortelazzo S, Majolino I, Mirto S, Corradini P, Boccadoro M, Saglio G, Pizzolo G, Barbui T, Gianni AM, Tarella C., CICERI , FABIO, Zanni, M, Magni, M, Rambaldi, A, Benedetti, F, Passera, R, Patti, C, Parvis, G, Ciceri, Fabio, Gallamini, A, Cortelazzo, S, Majolino, I, Mirto, S, Corradini, P, Boccadoro, M, Saglio, G, Pizzolo, G, Barbui, T, Gianni, Am, and Tarella, C.

Published
2007

48. Impact of complete remission achievement on the survival of lymphoma patients undergoing high-dose sequential chemotherapy and autograft (HDS programme): a GITIL (Gruppo Italiano Terapie Innovative nei Linfomi) retrospective study on 1,266 patients

Author

Tarella C, Zanni M, Rambaldi S, Magni M, Sorio M, Passera R, Patti C, Gallamini A, Cortelazzo S, Majolino I, Mirto S, Boccadoro M, Corradini P, Benedetti F, Barbui T, Gianni AM, CICERI , FABIO, Tarella, C, Zanni, M, Rambaldi, S, Magni, M, Sorio, M, Passera, R, Patti, C, Ciceri, Fabio, Gallamini, A, Cortelazzo, S, Majolino, I, Mirto, S, Boccadoro, M, Corradini, P, Benedetti, F, Barbui, T, and Gianni, Am

Published
2007

49. Incidence and risk factors of secondary myelodysplastic syndromelacute leukemia occurrence following peripheral blood progenitor cell autograft: a GITIL (Gruppo Italiano Terapie Innovative Nei Linfomi) survey on 1266 lymphoma patients

Author

Zanni M, Magni M, Rambaldi A, Benedetti F, Rosato R, Passera R, Patti K, Gallamini A, Cortelazzo S, Majolino I, Mirto S, Corradini P, Boccadoro M, Andreini A, Barbui T, Gianni AM, Tarella C., CICERI , FABIO, Zanni, M, Magni, M, Rambaldi, A, Benedetti, F, Rosato, R, Passera, R, Patti, K, Ciceri, Fabio, Gallamini, A, Cortelazzo, S, Majolino, I, Mirto, S, Corradini, P, Boccadoro, M, Andreini, A, Barbui, T, Gianni, Am, and Tarella, C.

Published
2007

50. Rituximab markedly improves the efficacy of high-dose programmes with autograft for B-cell lymphoma: a multicentre GITIL survey on 957 patients

Author

Tarella C, Zanni M, Magni M, Benedetti F, Barbui T, Boccadoro M, Patti C, Gallamini A, Cortelazzo S, Majolino I, Mirto S, Corradini P, Passera R, Pizzolo G, Gianni AM, Rambaldi A., CICERI , FABIO, Tarella, C, Zanni, M, Magni, M, Benedetti, F, Barbui, T, Boccadoro, M, Patti, C, Ciceri, Fabio, Gallamini, A, Cortelazzo, S, Majolino, I, Mirto, S, Corradini, P, Passera, R, Pizzolo, G, Gianni, Am, and Rambaldi, A.

Published
2007

Catalog

Books, media, physical & digital resources
See catalog results